Cargando…
Risk, Prediction and Prevention of Hereditary Breast Cancer – Large-Scale Genomic Studies in Times of Big and Smart Data
Over the last two decades genetic testing for mutations in BRCA1 and BRCA2 has become standard of care for women and men who are at familial risk for breast or ovarian cancer. Currently, genetic testing more often also includes so-called panel genes, which are assumed to be moderate-risk genes for b...
Autores principales: | Wunderle, Marius, Olmes, Gregor, Nabieva, Naiba, Häberle, Lothar, Jud, Sebastian M., Hein, Alexander, Rauh, Claudia, Hack, Carolin C., Erber, Ramona, Ekici, Arif B., Hoyer, Juliane, Vasileiou, Georgia, Kraus, Cornelia, Reis, André, Hartmann, Arndt, Schulz-Wendtland, Rüdiger, Lux, Michael P., Beckmann, Matthias W., Fasching, Peter A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986564/ https://www.ncbi.nlm.nih.gov/pubmed/29880983 http://dx.doi.org/10.1055/a-0603-4350 |
Ejemplares similares
-
HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment
por: Wuerfel, Franziska M., et al.
Publicado: (2020) -
Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
por: Gass, Paul, et al.
Publicado: (2018) -
Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians
por: Gass, Paul, et al.
Publicado: (2018) -
Mammographic density and prognosis in primary breast cancer patients
por: Heindl, Felix, et al.
Publicado: (2021) -
Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy
por: Schrauder, Michael G., et al.
Publicado: (2019)